ECE2021 Audio Eposter Presentations Diabetes, Obesity, Metabolism and Nutrition (223 abstracts)
Cardiorenal outcomes and T2DM control in new users of SGLT2 inhibitors in combination therapy
Ihintza Larrañaga 1 , Cristina Goena Vives 2 , Maria Magdalena Arteaga Ossa 1 , Jose Francisco Egido Arroyo 3 , Begoña Maíz Alcorta 4 , Laura Mañas Alonso 2 , Laura Quintas Ovejero 2 , Ana Moreno Rodrigo 5 , Nerea Andrés Imaz 5 , Amaia Cristina Armentia Del Pozo 6 , Amaia Aspiazu Abasolo 4 , Ruth Agirrezabalaga Villar 7 , Irene Larrañaga Gomez 8 , Sara Diez Irizar 8 , Teresa Arana Suarez 3 , Naroa Rico Dadebat 3 & Josu Pérez Yéboles 1
1Osakidetza Basque Health Service- Mendaro Hospital, Endocrinology and Nutrition, Mendaro, Spain; 2Osakidetza Basque Health Service- Mendaro Hospital, Cardiology, Mendaro, Spain; 3Osakidetza Basque Health Service, Ermua Health Centre, Primary Care, Spain; 4Osakidetza Basque Health Service, Mutriku Health Centre, Primary Care, Spain; 5Osakidetza Basque Health Service- Mendaro Hospital, Internal Medicine, Spain; 6Osakidetza Basque Health Service, Eibar Health Centre, Primary Care, Spain; 7Osakidetza Basque Health Service, Soraluze Health Centre, Primary Care, Spain; 8Osakidetza Basque Health Service, Torrekua Health Centre, Primary Care, Spain
Introduction and objectives
SGT2i have changed the paradigm of T2DM management. Last guidelines insist on the importance of using newer glucose-lowering drugs with a demonstrated reduction in cardiovascular events (CVE). The aim of this study is twofold: to describe CVE, heart failure (HF) and renal function evolution; and to assess its efficacy in non-selected patients with T2DM initiating SGLT2i
Material and methods
Retrospective observational study that included T2DM patients with SGLT2i initiation (Empagliflozin, Dapagliflozin or Canagliflozin) between February 2018–2019 from 2 hospitals and 10 primary care centers for a 78.000 population area. We analyzed metabolic outcomes (changes in HBA1c, weight), renal function evolution and the development of CVE and HF at baseline and at the end of monitoring (February 2020).
Results
544 patients were included. 342 men (63%), with a mean age of 66 years (10.2% N = 55 ≥ 80 years). The mean follow-up was 22.6 ± 6.3 months. Baseline HbA1c mean was 7.9 ± 1.3%, BMI 31.5 ± 5.8 kg/m2, eGFR 83.6 ± 20.1 ml/min/1.73 m2 (12% below < 60) and diabetes duration was 12.5 ± 7.7 years. 23.4% of patients had albuminuria and 10.7% was on loop diuretic. 38% of the sample had underwent a transthoracic echocardiogram (TTE) before the SGLT2i was prescribed: 63 (11.6%) had had previous HF and 23 of them a decompensation in the past year. TTE was available in 88.9% of them with a mean ejection fraction of 48% comparing to 60.6% observed in 31.4% of patients with no HF history (P < 0.001). 32.5% (N = 177) were on insulin and SGTL2i was added as second, third or fourth line of treatment in 33%, 26.2% and 26.9% respectively. 16%(N = 87) of patients discontinued treatment due to side effects and they were older than those who continued the therapy (69.8 vs 65.3 years, P < 0.001). Nearly 50% were urinary tract and genital infections and in 31 subjects eGFR went < 30. CVE´s prevalence was 23.7% (N = 127) but new onset ones were infrequent and non-fatal (N = 19, 3.5%). HF occurred in 4.6% (N = 25) and 16 patients required hospitalization. During follow-up, there were 12 deaths (2.2%): 2 because of terminal HF (included in a palliative care program). At the end of monitoring, SGLT2i lowered HBA1c and BMI –0.9% and –1.3 kg/m2 respectively (P < 0.001) whereas eGFR remained stable (79.4 ± 22.6 ml/min/1.73 m2).
Conclusions
Our registry suggests that SGLT2i improve glycemic control and weight parameters while renal function was preserved with low rates of intolerance and/or adverse events such as heart failure, CVE and death.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more